Bookmarks

The mission of the New TB Drugs group is to accelerate the discovery and development of new drugs for the treatment of tuberculosis by bringing together the stakeholders in TB Drug Development, including the patients themselves.
The site features blogs, clinical research sites, upcoming meetings, grant opportunities, and resources.

Are global health policies good for public health in developing countries?
Dr Amar Jesani

Editor of the Indian Journal of Medical Ethics, and Faculty, Centre for Studies in Ethics and Rights (Anusandhan Trust), Mumbai, India

Wednesday 16 May 2012, 17:30-21:00
Wellcome Collection, 183 Euston Road, London NW1 2BE

RSVP

This event is open to all and free to attend but please book your place in advance.

Contact: Johanna White

jwhite@nuffieldbioethics.org
+44 (0)207 681 9619

Lecture synopsis

Global health policies are shaped by multiple institutions, not all of them working directly in the field of health. These institutions both co-operate and compete with each other. But the dominant ones among them share some common approaches: (a) applying the principles of liberal economics to public health; (b) favouring certain technological and managerial solutions in system reforms; and (c) above all, having a common epistemological view on science and on what constitutes evidence. The dominance of this political, ideological and intellectual framework facilitates the opening up of public health to the market, and connects it to national and international corporate interests. In his lecture, Amar Jesani will argue that these developments are in conflict with people’s aspirations for more equitable socio-economic development, and for universal access to health care in developing countries. He will use India as a case study to demonstrate these points.

HandsOn: Biobanks

Uppsala Konsert & Kongress
20-21 September 2012, Uppsala, Sweden

Biobanking has become hot, and rather quickly. The technology, the claims and the investments are increasing, but what is the value we are chasing? The route from a human biological sample and registry data to real benefit for patients and public health is complex. Many activities make up this route: funding, ethical review, sample and data collection, storage, bioanalysis and bioinformatics. Each is intended to add value, but how do we make sure we see and increase the benefits?

At this interactive conference we invite you to help understand and improve the activities in these value chains and bring more benefit to humanity. We will use Idea Labs, Hands-On Exhibitions, poster presentations and knowledge sharing to present, discuss and develop ideas for getting the best out of biobanking. We invite academy, industry, doctors, patient groups, policy makers, public representatives and legislators to share knowledge and concerns, and to contribute.